Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
Summary
What This Bill Does
The Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act amends Public Health Service Act section 1106. It updates the program purpose to cover treatment of sickle cell disease and prevention and treatment of complications, not only prevention and treatment in general. It continues federal use of grants, contracts, and cooperative agreements for sickle cell disease and other heritable blood disorders and reauthorizes $8.205 million for each of fiscal years 2025 through 2029. The bill sustains a disease-specific federal infrastructure for surveillance, prevention, treatment improvement, and research coordination.
Who Benefits and How
People with sickle cell disease benefit from continued federal support for treatment and complication-prevention work. Families affected by heritable blood disorders benefit from sustained surveillance, prevention, and treatment programs. Health centers and community providers benefit from grants and cooperative agreements that support disease-specific services. Researchers benefit from continued federal program authority and funding for data, surveillance, and treatment improvement.
Who Bears the Burden and How
The Department of Health and Human Services must administer grants, contracts, and cooperative agreements through fiscal year 2029. Federal taxpayers bear the cost of the $8.205 million annual authorization. Grant recipients must meet federal reporting and program requirements. Program administrators must track treatment and complication-prevention outcomes, not just general awareness activities.
Key Provisions
- Amends the federal program to include treatment and complication prevention for sickle cell disease.
- Authorizes grants, contracts, and cooperative agreements for sickle cell disease and other heritable blood disorders.
- Authorizes $8.205 million annually for fiscal years 2025 through 2029.
- Provides surveillance, prevention, treatment, and research infrastructure for affected communities.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
Reauthorizes federal sickle cell disease and heritable blood disorder grants and cooperative agreements at $8.205 million annually for fiscal years 2025 through 2029, while updating the program to cover treatment and complication prevention.
Key Policy Areas
Health Care, Sickle Cell Disease, Medical Research
Primary Purpose
Reauthorizes federal sickle cell disease and heritable blood disorder grants and cooperative agreements at $8.205 million annually for fiscal years 2025 through 2029, while updating the program to cover treatment and complication prevention.
Policy Domains
Resolution provisions
Identified Gains
- People with sickle cell disease
- Families affected by heritable blood disorders
- Health centers
- Researchers
Identified Costs
- Department of Health and Human Services
- Federal taxpayers
- Grant recipients
- Program administrators
Sponsors
Legislative Progress
In CommitteeMr. James (for himself, Mr. Veasey, Mr. Carter of Louisiana, …
Referred to the House Committee on Energy and Commerce.
Introduced in House
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Families affected by heritable blood disorders, Health centers, People with sickle cell disease
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology